

## Afinitor Disperz® (everolimus) – Expanded indication

- On April 10, 2018, the <u>FDA announced</u> the approval of <u>Novartis' Afinitor Disperz (everolimus)</u> tablets for oral suspension, for the adjunctive treatment of adult and pediatric patients aged 2 years and older with tuberous sclerosis complex (TSC)-associated partial-onset seizures.
  - Afinitor Disperz is also approved for the treatment of adult and pediatric patients aged 1 year and older with TSC who have subependymal giant cell astrocytoma that requires therapeutic intervention but cannot be curatively resected.
- Everolimus is also available as Afinitor® and Zortress® tablets.
  - Afinitor is approved to treat advanced hormone receptor-positive, HER2-negative breast cancer in postmenopausal women; advanced neuroendocrine tumors in adults, advanced renal cell carcinoma in adults, renal angiomyolipoma with TSC in adults; and subependymal giant cell astrocytoma with TSC in adults and pediatric patients.
  - Zortress is approved for the prophylaxis of organ rejection in kidney and liver transplantation in adults.
  - Consult Afinitor and Zortress drug labels for more detailed indication information.
- The efficacy of Afinitor Disperz for the expanded indication was demonstrated in the EXIST-3 study enrolling 366 patients with TSC-associated partial-onset seizures. Patients were randomized to receive Afinitor Disperz at a dose to achieve a low trough (LT) level (3 7 ng/mL) or a high trough (HT) level (9 15 ng/mL) or placebo. The major efficacy outcome was the percentage reduction in seizure frequency.
  - The median percentage reduction from baseline in seizure frequency was significantly greater among patients randomized to Afinitor Disperz LT (29.3%; 95% CI: 18.8, 41.9; p = 0.003) and HT (39.6%; 95% CI: 35.0, 48.7; p < 0.001) vs. placebo (14.9%; 95% CI: 0.1, 21.7).</p>
- The most common adverse reaction (≥ 30%) with Afinitor Disperz use in TSC-associated partialonset seizures was stomatitis.
- The recommended starting dose of Afinitor Disperz for TSC-associated partial-onset seizures is 5 mg/m² orally once daily until disease progression or unacceptable toxicity.
  - The dose should be titrated to attain trough concentrations of 5 ng/mL 15 ng/mL.
  - Consult the Afinitor Disperz drug label for dosing recommendations for other indications.



## optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.